Fourth Quarter Fiscal 2023 Financial Highlights(All comparisons are year-over-year unless otherwise noted) Revenues of $22.5 million compared to $39.2 million […]
~ Patients treated with AMT-130 continue to show evidence of preserved neurological function with potential dose-dependent clinical benefits relative to […]
PITTSBURGH, Dec. 19, 2023 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on […]